What is Adaptimmune Therapeutics plc American's earnings per share (EPS)?

Adaptimmune Therapeutics plc American (ADAP) reported diluted earnings per share of -$0.05 for fiscal year 2024. This represents a 44.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Adaptimmune Therapeutics plc American (ADAP) Financials

ADAP

Trailing 12 months to June 30, 2025

Revenue $65.1M -54.0% YoY

Net Income -$169.8M -134.1% YoY

EPS (Diluted) -$0.05 FY2024 annual

Free Cash Flow -$191.7M -316.4% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2025, ended Jun 30, 2025 Reported Aug 13, 2025 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2025, filed Aug 13, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ADAP SEC filings page.

Adaptimmune Therapeutics plc American (ADAP) reported $65.1M in revenue over the twelve months to Jun 30, 2025, down 54.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ADAP FY2024 2026-10-03

Revenue has arrived, but Adaptimmune still operates like a development-stage business: nearly all gross profit is absorbed by research and overhead.

FY2024's revenue surge produced effectively 100.0% gross margin, yet operating cash flow remained negative at -$73.2M; the contrast indicates revenue is not yet self-funding because operating costs still exceed cash generated. Even as operating loss narrowed from FY2023, R&D reached $149.1M, pointing to continued development spending rather than a mature profit engine.

Current ratio was 2.9x, indicating short-term assets exceeded short-term obligations, but that coverage does not describe long-term balance-sheet strength. Total liabilities were $234.1M against equity of $11.8M; this leaves a thin accounting cushion beneath the company's obligations.

Operating cash flow improved from -$140.9M in FY2023 to -$73.2M in FY2024, but remained negative; the revenue increase reduced cash pressure without making operations self-financing. Capex was only $886K, so the remaining cash requirement reflects operating costs rather than physical expansion.

Financial Health Signals

Financial Health Score 46/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2024. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Adaptimmune Therapeutics plc American's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Not available for Adaptimmune Therapeutics plc American, and counted as zero in the overall score.

Dilution

Adaptimmune Therapeutics plc American had 1.54B shares outstanding at the end of fiscal year 2024, against 1.36B in fiscal year 2023. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Adaptimmune Therapeutics plc American scores 31/100 among other emerging companies.

R&D Intensity

Adaptimmune Therapeutics plc American spent $149.1M on research and development in fiscal year 2024, which was 60.4% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Adaptimmune Therapeutics plc American scores 83/100 among other emerging companies.

Revenue Progress

Adaptimmune Therapeutics plc American reported revenue of $178.0M in fiscal year 2024, against $60.3M in fiscal year 2023. Revenue Progress ranks emerging companies on the three-year path of that line, and Adaptimmune Therapeutics plc American scores 89/100 among other emerging companies.

Burn Trend

Adaptimmune Therapeutics plc American's operations used $73.2M of cash in fiscal year 2024, against $140.9M used in fiscal year 2023. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Adaptimmune Therapeutics plc American scores 71/100 among other emerging companies.

Balance Sheet

Not available for Adaptimmune Therapeutics plc American, and counted as zero in the overall score.

Altman Z-Score Distress

-5.79

Adaptimmune Therapeutics plc American scores -5.79, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($14.6M) relative to total liabilities ($234.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/7

Adaptimmune Therapeutics plc American passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Adaptimmune Therapeutics plc American reported a net loss of $70.8M while operations used $73.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Adaptimmune Therapeutics plc American reported an operating loss of $68.8M against $3.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$13.7M

YoY-89.3%

QoQ+87.7%

5Y CAGR+93.7%

Adaptimmune Therapeutics plc American generated $13.7M in revenue in Q2 2025. This represents a decrease of 89.3% from the same quarter a year earlier. Against the prior quarter it is up 87.7%.

Net Income

-$30.3M

YoY-143.6%

QoQ+36.2%

Adaptimmune Therapeutics plc American reported -$30.3M in net income in Q2 2025. This represents a decrease of 143.6% from the same quarter a year earlier. Against the prior quarter it is up 36.2%.

EPS (Diluted)

-$0.02

YoY-150.0%

QoQ+33.3%

Adaptimmune Therapeutics plc American earned -$0.02 per diluted share (EPS) in Q2 2025. This represents a decrease of 150.0% from the same quarter a year earlier. Against the prior quarter it is up 33.3%.

EBITDA

Not reported for Q2 2025.

Cash & Balance Sheet

Free Cash Flow

-$34.9M

YoY-174.2%

QoQ+48.6%

Adaptimmune Therapeutics plc American recorded an outflow of $34.9M in free cash flow in Q2 2025, representing a cash shortfall after capex. This represents a decrease of 174.2% from the same quarter a year earlier. Against the prior quarter it is up 48.6%.

Cash & Debt

$26.1M

YoY-87.7%

QoQ-36.5%

5Y CAGR-26.6%

10Y CAGR-19.5%

Adaptimmune Therapeutics plc American held $26.1M in cash against $25.7M in long-term debt as of Q2 2025.

Shares Outstanding

1.59B

YoY+3.6%

QoQ+3.0%

5Y CAGR+11.4%

Adaptimmune Therapeutics plc American had 1.59B shares outstanding in Q2 2025. This represents an increase of 3.6% from the same quarter a year earlier. Against the prior quarter it is up 3.0%.

Dividends Per Share

Not reported for Q2 2025.

Margins & Returns

Gross Margin

81.7%

QoQ-6.2pp

Adaptimmune Therapeutics plc American's gross margin was 81.7% in Q2 2025, indicating the percentage of revenue retained after direct costs. Against the prior quarter it is down 6.2 percentage points.

Operating Margin

Not shown for Q2 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for Q2 2025.

Capital Allocation

R&D Spending

$23.0M

YoY-43.2%

QoQ-20.4%

5Y CAGR+2.3%

Adaptimmune Therapeutics plc American invested $23.0M in research and development in Q2 2025. This represents a decrease of 43.2% from the same quarter a year earlier. Against the prior quarter it is down 20.4%.

Capital Expenditures

$75K

YoY-82.2%

QoQ-93.8%

5Y CAGR-22.5%

Adaptimmune Therapeutics plc American invested $75K in capex in Q2 2025, funding long-term assets and infrastructure. This represents a decrease of 82.2% from the same quarter a year earlier. Against the prior quarter it is down 93.8%.

Share Buybacks

Not reported for Q2 2025.

ADAP Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ADAP quarterly income statement

Metric	TTM	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Revenue	$65.1M	$178.0M+195.3%	$60.3M+122.0%	$27.1M+341.5%	$6.1M+55.4%	$4.0M+252.8%	$1.1M-98.1%	$59.5M+57.3%	$37.8M+166.5%	$14.2M+43.8%	$9.9M+1096.5%	$825K	N/A
Cost of Revenue	N/A	$70K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	$178.0M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$125.2M	$149.1M+17.8%	$126.5M-1.0%	$127.7M+15.0%	$111.1M+21.3%	$91.6M-6.1%	$97.5M-0.8%	$98.3M+12.5%	$87.4M+37.0%	$63.8M+164.3%	$24.1M+152.1%	$9.6M+27.8%	$7.5M
SG&A Expenses	$90.2M	$87.3M+18.7%	$73.5M+16.0%	$63.4M+10.6%	$57.3M+25.1%	$45.8M+5.5%	$43.4M-0.5%	$43.6M+40.2%	$31.1M+34.0%	$23.2M+123.7%	$10.4M+274.4%	$2.8M+121.0%	$1.3M
Operating Income	-$164.2M	-$68.8M+50.8%	-$139.7M+14.8%	-$164.0M-1.1%	-$162.2M-21.6%	-$133.4M+4.6%	-$139.8M-69.7%	-$82.4M-2.1%	-$80.7M-10.8%	-$72.8M-195.4%	-$24.6M-113.9%	-$11.5M-31.7%	-$8.7M
EBITDA	N/A	-$57.5M+55.7%	-$129.9M+17.7%	-$157.9M-1.4%	-$155.7M-23.7%	-$125.8M+4.5%	-$131.8M-76.7%	-$74.6M+0.9%	-$75.2M-8.2%	-$69.5M-190.8%	-$23.9M-111.9%	-$11.3M-29.6%	-$8.7M
Interest Expense	N/A	$3.3M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$3.7M	$3.6M+167.7%	$1.3M-46.5%	$2.5M+215.7%	$791K+388.3%	$162K-33.1%	$242K-51.3%	$497K+10.2%	$451K-49.4%	$892K+265.6%	$244K+225.3%	$75K	N/A
Net Income	-$169.8M	-$70.8M+37.8%	-$113.9M+31.2%	-$165.5M-4.7%	-$158.1M-21.5%	-$130.1M+5.2%	-$137.2M-43.6%	-$95.5M-36.2%	-$70.1M+2.0%	-$71.6M-224.5%	-$22.1M-90.1%	-$11.6M-32.7%	-$8.7M
EPS (Basic)	N/A	-$0.05+44.4%	-$0.09+47.1%	-$0.170.0%	-$0.17-13.3%	-$0.15+31.8%	-$0.22	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$0.05+44.4%	-$0.09+47.1%	-$0.170.0%	-$0.17-13.3%	-$0.15+31.8%	-$0.22	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	1.51B+25.5%	1.21B+24.7%	967M+3.5%	935M+9.4%	855M+35.7%	630M	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2510-Q	Q1'25	Q4'2410-Q	Q3'24	Q2'2410-Q	Q1'24	Q4'23	Q3'23
Revenue	$13.7M-89.3%	$7.3M+28.3%	$3.2M+1294.8%	$40.9M+458.8%	$128.2M+2399.6%	$5.7M-88.1%	$231K-97.9%	$7.3M+4.5%
Cost of Revenue	$2.5M	$879K	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	$11.2M	$6.4M	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$23.0M-43.2%	$28.9M-18.0%	$39.1M+17.7%	$34.3M-9.2%	$40.4M+35.0%	$35.2M+37.8%	$33.2M+44.1%	$37.8M+13.9%
SG&A Expenses	$18.5M-3.1%	$23.3M+18.0%	$27.2M+61.0%	$21.3M+31.6%	$19.1M-4.9%	$19.7M-3.3%	$16.9M+10.9%	$16.2M-3.9%
Operating Income	-$30.3M-144.1%	-$45.7M+7.2%	-$73.5M-47.5%	-$14.7M+68.5%	$68.7M+253.0%	-$49.3M-3074.7%	-$49.9M-83.0%	-$46.6M-8.5%
EBITDA	N/A	-$43.4M+6.6%	N/A	N/A	N/A	-$46.5M-1502.4%	N/A	N/A
Interest Expense	$962K+82.9%	$1.9M	N/A	$1.1M	$526K	N/A	N/A	N/A
Income Tax	$612K+16.3%	$575K+9.3%	$1.7M+358.1%	$831K+21.0%	$526K-22.6%	$526K-15.8%	-$656K-166.0%	$687K+72.2%
Net Income	-$30.3M-143.6%	-$47.6M+1.9%	-$74.2M-54.9%	-$17.6M+61.4%	$69.5M+425.0%	-$48.5M-4781.8%	-$47.9M-63.8%	-$45.6M-10.1%
EPS (Basic)	-$0.02-140.0%	-$0.030.0%	N/A	-$0.01+66.7%	$0.05+350.0%	-$0.03	N/A	-$0.03+25.0%
EPS (Diluted)	-$0.02-150.0%	-$0.030.0%	N/A	-$0.01+66.7%	$0.04	-$0.03	N/A	-$0.03+25.0%
Diluted Shares (Avg)	1.58B+1.6%	1.54B+6.3%	N/A	1.53B+13.0%	1.56B	1.45B+45.1%	N/A	1.36B+38.4%

ADAP Balance Sheet

ADAP quarterly balance sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Total Assets	$246.0M-13.0%	$282.6M-14.1%	$328.9M-30.0%	$469.5M+4.1%	$451.1M+148.5%	$181.5M-34.4%	$276.7M-1.6%	$281.1M+19.9%	$234.5M-22.0%	$300.7M+439.4%	$55.7M	N/A
Current Assets	$188.2M-9.3%	$207.6M-18.7%	$255.4M-38.5%	$415.5M+4.3%	$398.2M+230.4%	$120.5M-47.9%	$231.1M+0.4%	$230.2M+15.8%	$198.8M-32.6%	$295.1M+443.4%	$54.3M	N/A
Cash & Equivalents	$91.1M-36.7%	$144.0M+33.3%	$108.0M-28.0%	$149.9M+163.6%	$56.9M+12.8%	$50.4M-26.3%	$68.4M-18.6%	$84.0M-47.1%	$158.8M-30.7%	$229.0M+347.5%	$51.2M	N/A
Inventory	$7.3M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$1.5M+77.1%	$821K-89.0%	$7.4M+888.7%	$752K+441.0%	$139K	N/A	$192K-6.8%	$206K-86.1%	$1.5M+36900.0%	$4K-97.1%	$138K	N/A
Total Liabilities	$234.1M-3.7%	$243.1M-1.6%	$247.0M-6.3%	$263.6M+139.8%	$109.9M+89.8%	$57.9M+94.0%	$29.9M-61.8%	$78.2M+14.3%	$68.4M+64.2%	$41.6M-21.1%	$52.8M	N/A
Current Liabilities	$64.5M-11.3%	$72.8M+12.8%	$64.5M+3.1%	$62.5M+60.1%	$39.1M+13.8%	$34.3M+40.5%	$24.4M-67.1%	$74.3M+84.5%	$40.3M+50.5%	$26.8M-49.3%	$52.8M	N/A
Non-Current Liabilities	$169.6M-0.4%	$170.3M-6.7%	$182.5M-9.2%	$201.0M+183.8%	$70.8M+200.6%	$23.6M+335.2%	$5.4M+40.7%	$3.8M-86.3%	$28.1M+88.8%	$14.9M	$0	N/A
Long-Term Debt	$50.2M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$11.8M-70.0%	$39.5M-51.7%	$81.9M-60.2%	$206.0M-39.6%	$341.2M+176.0%	$123.6M-49.9%	$246.9M+21.6%	$203.0M+22.2%	$166.1M-35.9%	$259.0M+8659.0%	$3.0M+237.2%	-$2.2M
Retained Earnings	-$1.1B-6.9%	-$1.0B-12.5%	-$909.3M-22.2%	-$743.8M-27.0%	-$585.8M-28.5%	-$455.7M-43.1%	-$318.5M-37.5%	-$231.6M-43.4%	-$161.5M-141.3%	-$66.9M-122.2%	-$30.1M	N/A

Metric	Q2'2510-Q	Q1'25	Q4'2410-Q	Q3'24	Q2'2410-Q	Q1'24	Q4'23	Q3'23
Total Assets	$130.6M-59.4%	$158.1M-38.7%	$246.0M-13.0%	$317.4M+7.0%	$321.7M-6.2%	$258.0M-10.4%	$282.6M-14.1%	$296.6M-10.7%
Current Assets	$78.1M-69.2%	$103.0M-44.9%	$188.2M-9.3%	$244.2M+11.3%	$253.8M-3.1%	$186.9M-12.6%	$207.6M-18.7%	$219.4M-16.9%
Cash & Equivalents	$26.1M-87.7%	$41.1M-70.8%	$91.1M-36.7%	$116.7M+29.6%	$211.8M+175.2%	$140.7M+17.4%	$144.0M+33.3%	$90.1M+14.0%
Inventory	$11.4M	$11.8M	$7.3M	$1.9M	N/A	N/A	N/A	N/A
Accounts Receivable	$9.3M+298.8%	$4.4M-47.9%	$1.5M+77.1%	$12.5M+1484.3%	$2.3M-21.4%	$8.4M+390.0%	$821K-89.0%	$789K-55.5%
Total Liabilities	$201.6M-10.6%	$195.5M-16.3%	$234.1M-3.7%	$237.4M+13.9%	$225.4M+4.2%	$233.6M+14.4%	$243.1M-1.6%	$208.5M-4.7%
Current Liabilities	$51.5M-37.2%	$51.1M-23.1%	$64.5M-11.3%	$63.5M-15.6%	$82.1M+7.8%	$66.4M+4.4%	$72.8M+12.8%	$75.1M+13.7%
Non-Current Liabilities	$150.1M+4.7%	$144.4M-13.6%	$169.6M-0.4%	$174.0M+30.5%	$143.4M+2.2%	$167.2M+19.0%	$170.3M-6.7%	$133.4M-12.7%
Long-Term Debt	$25.7M+2.9%	$25.4M	$50.2M	$49.9M	$25.0M	N/A	N/A	N/A
Total Equity	-$71.0M-173.7%	-$37.4M-253.6%	$11.8M-70.0%	$80.0M-9.2%	$96.3M-24.0%	$24.4M-70.9%	$39.5M-51.7%	$88.1M-22.2%
Retained Earnings	-$1.2B-16.9%	-$1.1B-6.5%	-$1.1B-6.9%	-$1.0B-4.6%	-$1.0B-7.8%	-$1.1B-18.0%	-$1.0B-12.5%	-$975.3M-10.8%

Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Goodwill.

ADAP Cash Flow Statement

ADAP quarterly cash flow statement

Metric	TTM	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Operating Cash Flow	-$190.0M	-$73.2M+48.0%	-$140.9M+0.6%	-$141.8M-1421.4%	$10.7M+120.0%	-$53.6M+52.4%	-$112.5M-7.8%	-$104.4M-92.2%	-$54.3M-12.8%	-$48.2M-62.4%	-$29.7M-180.5%	$36.8M+445.1%	-$10.7M
Depreciation & Amortization	N/A	$11.2M+14.1%	$9.8M+62.0%	$6.1M-7.5%	$6.6M-13.5%	$7.6M-5.2%	$8.0M+2.6%	$7.8M+44.0%	$5.4M+65.0%	$3.3M+347.1%	$735K+206.3%	$240K+410.6%	$47K
Stock-Based Compensation	N/A	$12.1M+2.4%	$11.8M-35.5%	$18.2M-11.6%	$20.6M+98.1%	$10.4M-5.8%	$11.1M-31.8%	$16.2M+50.0%	$10.8M+22.5%	$8.8M+24.6%	$7.1M+2031.9%	$332K+86.5%	$178K
Capital Expenditures	$1.6M	$886K-81.1%	$4.7M-84.1%	$29.5M+244.0%	$8.6M+266.3%	$2.3M+47.0%	$1.6M-59.3%	$3.9M-84.1%	$24.6M+114.2%	$11.5M+126.5%	$5.1M+271.9%	$1.4M+718.0%	$167K
Free Cash Flow	-$191.7M	-$74.1M+49.1%	-$145.6M+15.0%	-$171.3M-8047.3%	$2.2M+103.9%	-$55.9M+51.0%	-$114.1M-5.4%	-$108.3M-37.2%	-$79.0M-32.3%	-$59.7M-71.7%	-$34.7M-198.0%	$35.5M+427.2%	-$10.8M
Investing Cash Flow	$1.8M	-$59.0M-133.4%	$176.5M+98.1%	$89.1M+17.6%	$75.8M+127.2%	-$278.9M-393.8%	$94.9M+643.9%	-$17.5M+86.2%	-$126.1M-810.1%	$17.8M+130.2%	-$58.8M	N/A	N/A
Financing Cash Flow	$1.3M	$78.7M+8848.8%	$880K-93.2%	$12.9M+291.3%	$3.3M-99.0%	$340.1M+92810.1%	$366K-99.6%	$102.7M-0.8%	$103.6M+609123.5%	$17K-100.0%	$274.9M	N/A	N/A

Metric	Q2'2510-Q	Q1'25	Q4'2410-Q	Q3'24	Q2'2410-Q	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$34.8M-173.4%	-$66.6M-108.4%	-$34.2M-133.1%	-$54.5M-20.6%	$47.4M+208.3%	-$31.9M+14.3%	-$14.7M-818.7%	-$45.2M+6.2%
Depreciation & Amortization	N/A	$2.3M-17.3%	N/A	N/A	N/A	$2.8M+67.0%	N/A	N/A
Stock-Based Compensation	$1.3M-56.8%	$669K-78.4%	N/A	$3.1M-4.1%	$3.1M-20.3%	$3.1M+85.1%	N/A	$3.2M-13.1%
Capital Expenditures	$75K-82.2%	$1.2M+1079.4%	$219K-73.5%	$143K-50.5%	$422K-65.3%	$102K-95.7%	$827K-75.8%	$289K-97.1%
Free Cash Flow	-$34.9M-174.2%	-$67.8M-111.5%	-$34.4M-122.0%	-$54.6M-20.1%	$47.0M+204.4%	-$32.1M+19.1%	-$15.5M-1029.1%	-$45.4M+21.9%
Investing Cash Flow	$18.5M+2588.6%	$41.2M+11595.5%	$8.2M-88.0%	-$66.0M-215.2%	-$743K-127.6%	-$358K-100.7%	$68.2M+225.5%	$57.3M+98.6%
Financing Cash Flow	$1.7M-93.3%	-$25.3M-186.6%	$1K-98.6%	$25.0M+4094.8%	$24.5M+174985.7%	$29.2M+14815.8%	$74K-94.7%	$596K-59.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ADAP Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ADAP quarterly financial ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13
Gross Margin	100.0%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-38.6%	-231.8%	-604.0%	-2638.6%	-3370.5%	-12457.2%	-138.4%	-213.2%	-512.7%	-249.6%	-1396.5%	N/A
Net Margin	-39.8%	-188.9%	-609.5%	-2571.0%	-3286.8%	-12225.0%	-160.5%	-185.4%	-504.2%	-223.5%	-1406.2%	N/A
Return on Equity	-597.6%-309.4pp	-288.2%-86.1pp	-202.1%-125.3pp	-76.8%-38.6pp	-38.1%+72.8pp	-110.9%-72.2pp	-38.7%-4.1pp	-34.5%+8.5pp	-43.1%-34.6pp	-8.5%+383.8pp	-392.3%	N/A
Return on Assets	-28.8%+11.5pp	-40.3%+10.0pp	-50.3%-16.6pp	-33.7%-4.8pp	-28.8%+46.7pp	-75.6%-41.1pp	-34.5%-9.6pp	-24.9%+5.6pp	-30.5%-23.2pp	-7.3%+13.5pp	-20.8%	N/A
Current Ratio	2.92+0.1x	2.85-1.1x	3.96-2.7x	6.64-3.5x	10.19+6.7x	3.51-5.9x	9.46+6.4x	3.10-1.8x	4.94-6.1x	11.02+10.0x	1.03	N/A
Debt-to-Equity	4.24-1.9x	6.15+3.1x	3.02+1.7x	1.28+1.0x	0.32-0.1x	0.47+0.3x	0.12-0.3x	0.390.0x	0.41+0.3x	0.16-17.7x	17.85	N/A
Asset Turnover	0.72+0.5x	0.21+0.1x	0.08+0.1x	0.010.0x	0.010.0x	0.01-0.2x	0.21+0.1x	0.13+0.1x	0.060.0x	0.030.0x	0.01	N/A
FCF Margin	-41.6%	-241.5%	-630.9%	35.0%	-1413.1%	-10169.3%	-182.0%	-208.7%	-420.3%	-352.0%	4299.3%	N/A

Metric	Q2'2510-Q	Q1'25	Q4'2410-Q	Q3'24	Q2'2410-Q	Q1'24	Q4'23	Q3'23
Gross Margin	81.7%	87.9%	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-221.5%	-627.8%	-2281.8%	-35.9%	53.6%	-867.6%	-21582.7%	-637.1%
Net Margin	-221.8%	-653.2%	-2303.4%	-43.1%	54.2%	-854.2%	-20743.3%	-623.1%
Return on Equity	N/A	N/A	-626.3%-505.1pp	-22.0%+29.7pp	72.2%+89.1pp	-199.0%-200.2pp	-121.3%-85.5pp	-51.7%-15.2pp
Return on Assets	-23.2%-44.8pp	-30.1%-11.3pp	-30.2%-13.2pp	-5.5%+9.8pp	21.6%+27.8pp	-18.8%-19.2pp	-17.0%-8.1pp	-15.4%-2.9pp
Current Ratio	1.52-1.6x	2.02-0.8x	2.92+0.1x	3.85+0.9x	3.09-0.3x	2.81-0.5x	2.85-1.1x	2.92-1.1x
Debt-to-Equity	N/A	N/A	4.24-1.9x	0.62-1.7x	0.26-1.4x	9.59+7.2x	6.15+3.1x	2.37+0.4x
Asset Turnover	0.10-0.3x	0.050.0x	0.010.0x	0.13+0.1x	0.40+0.4x	0.02-0.1x	0.000.0x	0.020.0x
FCF Margin	-254.8%	-930.6%	-1068.4%	-133.5%	36.6%	-564.5%	-6711.3%	-621.0%

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Adaptimmune Therapeutics plc American ADAP	FY2024	$178.0M	-$70.8M	-39.8%	$14.6M	46/100
Briacell Therapeutics Corp. BCTX	FY2025	N/A	-$26.3M	N/A	$35.0M	—
Marker Therapeutics, Inc. MRKR	FY2025	$3.5M	-$12.2M	N/A	$16.8M	59/100
Apollomics Inc. APLM	FY2025	$8.5M	-$10.9M	N/A	$64.4M	30/100
Phio Pharmaceuticals Corp. PHIO	FY2025	N/A	-$8.7M	N/A	$11.5M	—

Where Adaptimmune Therapeutics plc American Ranks

Frequently Asked Questions

What is Adaptimmune Therapeutics plc American's annual revenue?

Adaptimmune Therapeutics plc American (ADAP) reported $178.0M in total revenue for fiscal year 2024. This represents a 195.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Adaptimmune Therapeutics plc American's revenue growing?

Adaptimmune Therapeutics plc American (ADAP) revenue grew by 195.3% year-over-year, from $60.3M to $178.0M in fiscal year 2024.

Is Adaptimmune Therapeutics plc American profitable?

No, Adaptimmune Therapeutics plc American (ADAP) reported a net income of -$70.8M in fiscal year 2024, with a net profit margin of -39.8%.

What is Adaptimmune Therapeutics plc American's EBITDA?

Adaptimmune Therapeutics plc American (ADAP) had EBITDA of -$57.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Adaptimmune Therapeutics plc American have?

As of fiscal year 2024, Adaptimmune Therapeutics plc American (ADAP) had $91.1M in cash and equivalents against $50.2M in long-term debt.

What is Adaptimmune Therapeutics plc American's gross margin?

Adaptimmune Therapeutics plc American (ADAP) had a gross margin of 100.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Adaptimmune Therapeutics plc American's operating margin?

Adaptimmune Therapeutics plc American (ADAP) had an operating margin of -38.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Adaptimmune Therapeutics plc American's net profit margin?

Adaptimmune Therapeutics plc American (ADAP) had a net profit margin of -39.8% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Adaptimmune Therapeutics plc American's return on equity (ROE)?

Adaptimmune Therapeutics plc American (ADAP) has a return on equity of -597.6% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Adaptimmune Therapeutics plc American's free cash flow?

Adaptimmune Therapeutics plc American (ADAP) recorded an outflow of $74.1M in free cash flow during fiscal year 2024. This represents a 49.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Adaptimmune Therapeutics plc American's operating cash flow?

Adaptimmune Therapeutics plc American (ADAP) recorded an outflow of $73.2M in operating cash flow during fiscal year 2024, representing cash used by core business activities.

What are Adaptimmune Therapeutics plc American's total assets?

Adaptimmune Therapeutics plc American (ADAP) had $246.0M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Adaptimmune Therapeutics plc American's capital expenditures?

Adaptimmune Therapeutics plc American (ADAP) invested $886K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Adaptimmune Therapeutics plc American spend on research and development?

Adaptimmune Therapeutics plc American (ADAP) invested $149.1M in research and development during fiscal year 2024.

How many shares does Adaptimmune Therapeutics plc American have outstanding?

Adaptimmune Therapeutics plc American (ADAP) had 1.54B shares outstanding as of fiscal year 2024.

What is Adaptimmune Therapeutics plc American's current ratio?

Adaptimmune Therapeutics plc American (ADAP) had a current ratio of 2.92 as of fiscal year 2024, which is generally considered healthy.

What is Adaptimmune Therapeutics plc American's debt-to-equity ratio?

Adaptimmune Therapeutics plc American (ADAP) had a debt-to-equity ratio of 4.24 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Adaptimmune Therapeutics plc American's return on assets (ROA)?

Adaptimmune Therapeutics plc American (ADAP) had a return on assets of -28.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Adaptimmune Therapeutics plc American's Altman Z-Score?

Adaptimmune Therapeutics plc American (ADAP) has an Altman Z-Score of -5.79, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Adaptimmune Therapeutics plc American's Piotroski F-Score?

Adaptimmune Therapeutics plc American (ADAP) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Adaptimmune Therapeutics plc American's earnings high quality?

Adaptimmune Therapeutics plc American (ADAP) reported a net loss of $70.8M while operations used $73.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Adaptimmune Therapeutics plc American cover its interest payments?

Adaptimmune Therapeutics plc American (ADAP) reported an operating loss of $68.8M against $3.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Adaptimmune Therapeutics plc American?

Adaptimmune Therapeutics plc American (ADAP) scores 46 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.